Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$5.1 million.

  • Zevra Therapeutics' Non Operating Income rose 1349.89% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.3 million, marking a year-over-year increase of 493965.75%. This contributed to the annual value of -$3.1 million for FY2024, which is 18824.19% down from last year.
  • Per Zevra Therapeutics' latest filing, its Non Operating Income stood at -$5.1 million for Q3 2025, which was up 1349.89% from $147.9 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Non Operating Income peaked at $147.9 million during Q2 2025, and registered a low of -$17.3 million during Q1 2021.
  • Over the past 5 years, Zevra Therapeutics' median Non Operating Income value was $463000.0 (recorded in 2021), while the average stood at $7.7 million.
  • In the last 5 years, Zevra Therapeutics' Non Operating Income crashed by 130950.32% in 2022 and then surged by 365494.92% in 2025.
  • Over the past 5 years, Zevra Therapeutics' Non Operating Income (Quarter) stood at $173000.0 in 2021, then surged by 3434.1% to $6.1 million in 2022, then tumbled by 177.45% to -$4.7 million in 2023, then decreased by 4.58% to -$5.0 million in 2024, then dropped by 3.39% to -$5.1 million in 2025.
  • Its last three reported values are -$5.1 million in Q3 2025, $147.9 million for Q2 2025, and $3.4 million during Q1 2025.